V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220015138 | 220018262 | 1.55 | null | Curative (C) | 2015-04-22 | 2015-04-22 | DAUNORUBICIN | null | null | 220033588 | CVD |
| 220015139 | 220018262 | null | 71.6 | Curative (C) | 2017-01-07 | 2017-01-29 | Alemtuzumab+Busulfan+CyclophosphMUD | null | null | 220033588 | DAUNORUBICIN |
| 220015140 | 220015156 | 1.61 | 61.6 | null | 2013-09-11 | 2013-09-15 | FIGARO TRIAL | N | N | 220033759 | PEMBROLIZUMAB |
| 220015141 | 220009791 | 1.56 | 57 | Curative (C) | 2015-12-05 | 2015-12-05 | TRASTUZUMAB | N | N | 220033759 | HCX |
| 220015142 | 220009791 | null | 87.2 | Curative (C) | 2018-03-27 | 2018-03-29 | CAV | 2 | null | 220033759 | PEMBROLIZUMAB |
| 220015143 | 220009793 | 1.68 | 100.9 | Disease modification (D) | 2016-04-03 | 2016-06-04 | LENALIDOMIDE | 2 | N | 220034037 | CAPECITABINE + OXALIPLATIN |
| 220015144 | 220015159 | 1.67 | 66.8 | Disease modification (D) | 2013-11-08 | 2013-11-08 | Clofarabine+Cytarabine+Idarubicin | 02 | N | 220034048 | CAMELLIA TRIAL |
| 220015145 | 220009796 | 1.68 | 16.6 | Disease modification (D) | 2014-03-23 | 2014-03-23 | FIGARO TRIAL | 02 | null | 220034048 | MACE |
| 220015146 | 220009797 | 1.8 | null | Disease modification (D) | 2018-01-29 | 2019-05-05 | CISPLATIN + RT | null | null | 220034188 | FLUDARABINE |
| 220015147 | 220015162 | 1.79 | null | Curative (C) | 2017-09-09 | 2017-09-15 | BUSULFAN + CYCLO | 2 | N | 220034188 | EOF |
| 220015148 | 220009798 | 1.62 | 60.3 | Curative (C) | 2019-06-19 | 2019-06-20 | Bortezomib + Cyclophos + Dex | null | N | 220034295 | FLUDARABINE |
| 220015149 | 220009799 | 1.65 | 87.9 | null | 2018-07-21 | 2018-07-28 | ALL UKALL2011 Maintenance A3 | Y | N | 220034318 | DOXORUBICIN |
| 220015150 | 220009802 | null | null | null | 2014-06-26 | 2014-08-11 | LENALIDOMIDE | N | N | 220034508 | IGEV R |
| 220015151 | 220009807 | null | 80.3 | Palliative (P) | 2017-10-25 | 2017-11-02 | DAUNORUBICIN | N | N | 220034708 | IMATINIB + HYDROXYCARBAMIDE |
| 220015152 | 220009808 | null | null | Palliative (P) | null | 2018-01-29 | CLOFARABINE + DAUNORUBICIN | 99 | null | 220034781 | CARBOPLATIN |
| 220015153 | 220009810 | 1.67 | 94 | Curative (C) | 2018-03-15 | 2018-06-25 | Arsenic Triox + Tretinoin Ind W1-4 | 02 | N | 220034831 | LIPOSOMAL CYTARABINE |
| 220015154 | 220009811 | 0 | 46.4 | Palliative (P) | 2017-09-12 | 2017-10-14 | MERCAPTOPURINE + METHOTREXATE | 02 | N | 220035162 | GEMCITABINE |
| 220015155 | 220009811 | null | 113 | Curative (C) | null | 2017-05-24 | MITOXANTRONE + TRETINOIN | null | null | 220035162 | GEMCITABINE |
| 220015156 | 220009813 | 1.78 | 76.7 | Curative (C) | 2018-04-05 | 2018-04-05 | ALL UKALL2011 Maintenance A1 | N | N | 220035216 | PEMBROLIZUMAB |
| 220015157 | 220009814 | 1.69 | 84.8 | Curative (C) | 2015-05-20 | 2015-05-20 | BUSULFAN + CYCLO | N | N | 220035338 | CARBOPLATIN |
| 220015158 | 220009816 | 1.63 | null | Curative (C) | 2014-06-07 | 2014-06-10 | EC | N | null | 220035346 | VINCRISTINE |
| 220015159 | 220009817 | 1.7 | 65.3 | Curative (C) | 2015-11-01 | 2015-11-11 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 99 | N | 220035363 | CISPLATIN + PEMETREXED |
| 220015160 | 220009818 | null | 101.8 | Curative (C) | 2018-07-22 | 2018-07-27 | MERCAPTOPURINE + METHOTREXATE | N | N | 220035438 | PERTUZUMAB + TRASTUZUMAB |
| 220015161 | 220009818 | null | null | Curative (C) | 2013-11-06 | 2013-11-07 | CYTARABINE + Hydrocortisone + Hydrocortisone + METHOTREXATE | null | null | 220035438 | CAV |
| 220015162 | 220020020 | 0 | 69.6 | Curative (C) | 2013-08-17 | 2013-08-24 | Arsenic Trioxide (Induction Week) | 02 | N | 220035628 | UKALL2011 |
| 220015163 | 220009821 | 1.53 | 63 | Curative (C) | 2016-02-19 | 2016-02-20 | Ipilimumab | 2 | N | 220014565 | CISPLATIN + RT |
| 220015164 | 220009821 | 1.8 | 69.1 | null | 2016-04-08 | 2016-04-08 | CETUXIMAB + IRINOTECAN + MDG | N | N | 220014565 | MERCAPTOPURINE + METHOTREXATE |
| 220015165 | 220009822 | null | 99.7 | Curative (C) | 2014-12-17 | 2014-12-17 | MELPHALAN | N | N | 220020987 | EOX |
| 220015166 | 220009824 | null | 76 | Curative (C) | 2016-03-19 | 2016-04-07 | Sorafenib | 2 | N | 220023685 | LI-1 TRIAL |
| 220015167 | 220015170 | 1.77 | 89.5 | Curative (C) | 2019-04-14 | 2019-05-22 | Etoposide oral | N | N | 220024970 | RAVVA TRIAL |
| 220015168 | 220009826 | 1.66 | 120 | null | 2017-12-17 | 2017-12-21 | R GCVP | N | null | 220028568 | FLUDARABINE |
| 220015169 | 220015172 | 1.74 | 44.8 | Curative (C) | 2013-07-09 | 2013-07-09 | Etoposide oral | 02 | N | 220029487 | IRINOTECAN |
| 220015170 | 220009828 | 1.79 | null | null | 2017-11-19 | 2017-11-26 | IGEV R | N | null | 220032351 | CYTARABINE + FLUDARABINE |
| 220015171 | 220009829 | null | null | Curative (C) | 2016-11-03 | 2016-11-11 | Vincristine (weekly) | N | N | 220032604 | ETOPOSIDE + IDARUBICIN |
| 220015172 | 220015173 | null | 38.95 | Palliative (P) | 2017-03-06 | 2017-03-07 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | null | 220035180 | CISPLATIN + FLUOROURACIL |
| 220015173 | 220015173 | 1.67 | 62.2 | Palliative (P) | 2018-09-14 | 2018-10-26 | PEMBROLIZUMAB | N | N | 220035180 | PEMBROLIZUMAB |
| 220015174 | 220015174 | 1.77 | 56.6 | Curative (C) | 2016-02-08 | 2016-02-09 | Methotrexate High Dose (3g/m2) | N | N | 220034624 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 220015176 | 220004044 | null | 115 | Disease modification (D) | null | 2013-12-23 | IMATINIB | 2 | N | 220000022 | IMATINIB |
| 220015177 | 220012143 | null | null | Disease modification (D) | 2015-03-29 | 2015-03-29 | IMATINIB | N | N | 220000089 | IMATINIB |
| 220015178 | 220004047 | null | null | Disease modification (D) | 2016-04-26 | 2016-04-26 | Imatinib 400mg | null | N | 220000097 | IMATINIB |
| 220015179 | 220004050 | 1.69 | 71 | Disease modification (D) | 2013-04-25 | 2013-05-12 | Imatinib 400mg | N | N | 220000120 | IMATINIB |
| 220015180 | 220004053 | 1.81 | 150 | Disease modification (D) | 2015-02-13 | 2015-02-13 | Imatinib 400mg | 2 | N | 220000145 | IMATINIB |
| 220015181 | 220012145 | 0 | 0 | Disease modification (D) | 2018-03-29 | 2018-04-26 | IMATINIB | 02 | N | 220000151 | IMATINIB |
| 220015182 | 220004058 | null | 0 | Curative (C) | 2015-11-13 | 2015-11-13 | Imatinib 400mg | 02 | N | 220000211 | IMATINIB |
| 220015183 | 220004060 | 1.38 | 78.6 | Palliative (P) | null | 2016-09-21 | IMATINIB | N | N | 220000223 | IMATINIB |
| 220015185 | 220004066 | null | null | Disease modification (D) | 2017-05-08 | 2017-12-08 | IMATINIB | N | null | 220000374 | IMATINIB |
| 220015186 | 220004068 | null | 0 | Curative (C) | 2016-05-23 | 2017-04-18 | IMATINIB | 2 | N | 220000450 | IMATINIB |
| 220015187 | 220004075 | 0 | 0 | Disease modification (D) | 2014-05-31 | 2014-06-07 | Imatinib 400mg | N | N | 220000633 | IMATINIB |
| 220015188 | 220004078 | 1.55 | 0 | null | 2016-11-07 | 2016-11-08 | Imatinib 400mg | 2 | N | 220000637 | IMATINIB |
| 220015189 | 220004079 | 1.7 | null | Curative (C) | 2012-12-15 | 2014-01-24 | IMATINIB | 2 | N | 220000650 | IMATINIB |